Key facts
- This page summarizes Erick Lucera's Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 Dec 2025, 16:50.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.
Footnote F2
This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.